I think double digit royalties on CYP-001 would mean GvHD and also the other diseases they may option.
Am very happy with the double digit, so 10-15% which is the upper end given Fuji will bear the costs after GvHD.
So, FUJI said their target is $US300m for GvHD alone by 2023.
This would mean annual royalties of A$40m PA to Cynata at lowest double digit (10%).
I said recently, this would make current cap look good for this one treatment alone. (on NPV). let alone the extra $60m milestones $$
Ann: Cynata & FUJIFILM Sign Strategic Partnership Agreement, page-15
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.0¢ | $5.869K | 22.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29342 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.47pm 11/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |